The role of basal insulins in the treatment of people with type 2 diabetes and chronic kidney disease: A narrative review

被引：0

作者：

Sloan, Lance ^{[1
,2
]}

Cheng, Alice Y. Y. ^{[3
]}

Escalada, Javier ^{[4
,5
,6
]}

Haluzik, Martin ^{[7
]}

Mauricio, Didac ^{[8
,9
,10
,11
]}

机构：

[1] Texas Inst Kidney & Endocrine Disorders, Lufkin, TX 75904 USA

[2] Univ Texas Med Branch, Galveston, TX USA

[3] Univ Toronto, Trillium Hlth Partners & Unity Hlth, Toronto, ON, Canada

[4] Clin Univ Navarra, Dept Endocrinol & Nutr, Pamplona, Spain

[5] Inst Salud Carlos III, Ctr Biomed Res Physiopathol Obes & Nutr CIBERobn, Madrid, Spain

[6] Inst Invest Sanitaria Navarra IdiSNA, Pamplona, Spain

[7] Inst Clin & Expt Med, Diabet Ctr, Prague, Czech Republic

[8] Inst Salud Carlos III, Ctr Biomed Res Diabet & Associated Metab Dis CIBER, Barcelona, Spain

[9] Hosp Santa Creu & Sant Pau, Dept Endocrinol & Nutr, CIBERDEM, Barcelona, Spain

[10] St Pau Biomed Res Inst IIB St Pau, Barcelona, Spain

[11] Univ Vic UVIC UCC, Fac Med, Vic, Spain

来源：

DIABETES OBESITY & METABOLISM | 2024年 / 26卷 / 04期

关键词：

basal insulin; diabetes complications; diabetic nephropathy; hypoglycaemia; type; 2; diabetes; GLOMERULAR-FILTRATION-RATE; HYPOGLYCEMIA; GLARGINE; MANAGEMENT; DEGLUDEC; PHARMACOKINETICS;

D O I：

10.1111/dom.15425

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The majority of cases of chronic kidney disease (CKD) worldwide are driven by the presence of type 2 diabetes (T2D), resulting in an increase in CKD rates over the past few decades. The existence of CKD alongside diabetes is associated with increased burden of cardiovascular disease and increased risk of death. Optimal glycaemic control is essential to prevent progression of CKD, but achieving glycaemic targets in people with CKD and diabetes can be challenging because of increased risk of hypoglycaemia and limitations on glucose-lowering therapeutic options. This review considers the challenges in management of T2D in people with impaired kidney function and assesses evidence for use of basal insulin analogues in people with CKD.

引用

页码：1157 / 1170

页数：14

共 68 条

[1] Diabetic Kidney Disease Challenges, Progress, and Possibilities
Alicic, Radica Z.
Rooney, Michele T.
Tuttle, Katherine R.
[J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2017, 12 (12): : 2032 - 2045
[2] Hypoglycemia in Patients with Diabetes and Renal Disease
Alsahli, Mazen
Gerich, John E.
[J]. JOURNAL OF CLINICAL MEDICINE, 2015, 4 (05) : 948 - 964
[3] 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022
American Diabetes Association Professional Practice Committee
[J]. DIABETES CARE, 2022, 45 : S125 - S143
[4] Amod A, 2020, DIABETES THER, V11, P53, DOI [10.1007/s13300-019-00715-x, 10.2337/dci19-0066]
[5] Target attainment in insulin-naive patients at high risk for hypoglycemia: Results from ACHIEVE Control
Anderson, John
Meneghini, Luigi
Hinnen, Debbie
Gill, Jasvinder
Coudert, Mathieu
Evenou, Pierre
Munshi, Medha
[J]. JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2021, 35 (04)
[6] [Anonymous], 2015, TRESIBA PRESCRIBING
[7] [Anonymous], 2022, LEVEMIR PRESCRIBING
[8] [Anonymous], 2019, LANTUS PRESCRIBING I
[9] Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
Bakris, George L.
Agarwal, Rajiv
Anker, Stefan D.
Pitt, Bertram
Ruilope, Luis M.
Rossing, Peter
Kolkhof, Peter
Nowack, Christina
Schloemer, Patrick
Joseph, Amer
Filippatos, Gerasimos
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (23) : 2219 - 2229
[10] New Insulin Glargine 300 Units.mL-1 Provides a More Even Activity Profile and Prolonged Glycemic Control at Steady State Compared With Insulin Glargine 100 Units.mL-1
Becker, Reinhard H. A.
Dahmen, Raphael
Bergmann, Karin
Lehmann, Anne
Jax, Thomas
Heise, Tim
[J]. DIABETES CARE, 2015, 38 (04) : 637 - 643

← 1 2 3 4 5 6 7 →